Abstract
Clofarabine (1) is an anticancer agent used to treat acute leukemia. This work discloses the efforts to develop a convenient, environmentally benign, and high-yielding synthetic protocol leading to Clofarabine (1). The synthesis includes bromination of 2-deoxy-2-β-fluoro-1,3,5-tri-O-benzoyl-1- α-D-ribofuranose (6), followed by C-N coupling with a 2,6-dichloro purine (4) and selective amination consecutively. The proposed total synthesis comprises five steps to afford an overall yield of 65- 70% with 99.85% purity. The present process provides preparation of Clofarabine (1) using a simple purification process with lesser reaction time, better yield, and purity without using toxic and pyrophoric chemicals.
Graphical Abstract
[http://dx.doi.org/10.1002/cbdv.200490033] [PMID: 17191854]
[http://dx.doi.org/10.1021/jm060217p] [PMID: 16854061]
[http://dx.doi.org/10.1016/j.bmc.2005.12.060] [PMID: 16503144]
[http://dx.doi.org/10.1016/j.pharmthera.2007.07.004] [PMID: 17884172]
[http://dx.doi.org/10.1021/cc060053y] [PMID: 16961399]
[http://dx.doi.org/10.1021/jm00242a004] [PMID: 808609]
[http://dx.doi.org/10.1021/jm00251a015] [PMID: 4830257]
[PMID: 1707752]
[PMID: 11705880]
[http://dx.doi.org/10.1021/jm00080a029] [PMID: 1732556]
[http://dx.doi.org/10.1073/pnas.89.7.2970] [PMID: 1348362]
[http://dx.doi.org/10.1016/0731-7085(95)01325-F] [PMID: 9696594]
[http://dx.doi.org/10.1021/jm00090a001]
[http://dx.doi.org/10.1016/j.tetlet.2012.05.032]
[http://dx.doi.org/10.1002/ejoc.201101601]
[http://dx.doi.org/10.1080/00397911.2020.1858109]
[http://dx.doi.org/10.1016/j.tetlet.2023.154627]
[http://dx.doi.org/10.1016/0040-4039(95)02102-7]
[http://dx.doi.org/10.1021/op049884n]